SCHEMBL24345458

SCHEMBL24345458

COc1cc(C(=O)NCC(O)(c2cc3c(c(-c4ccc(F)cc4)n2)OC[C@]3(C)CO)C(F)(F)F)cc2cccnc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.37
CFTR P13569 3/20 0.33
KMT2A Q03164 5/20 0.33
MEN1 O00255 4/20 0.33
HPGD P15428 2/20 0.33
GABRA5 P31644 3/20 0.32
MAPT P10636 2/20 0.32
LMNA P02545 1/20 0.32
TACR1 P25103 1/20 0.31
DYRK1A Q13627 1/20 0.31
ALDH1A1 P00352 1/20 0.30
TP53 P04637 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
HSD17B10 Q99714 1/20 0.30
MAPK13 O15264 1/20 0.30
MAPK12 P53778 1/20 0.30
MAPK11 Q15759 1/20 0.30
MAPK14 Q16539 1/20 0.30
NR3C1 P04150 1/20 0.30
NR3C2 P08235 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23905707 0.94 POLB (0.35) POLBKMT2AMEN1HPGDMAPT
SCHEMBL24345299 0.94 POLB (0.36) POLBCFTRKMT2AMEN1HPGD
SCHEMBL24345459 0.93 POLB (0.39) POLBCFTRKMT2AMEN1HPGD
SCHEMBL24985386 0.93 POLB (0.36) POLBCFTRKMT2AMEN1HPGD
SCHEMBL24985387 0.93 POLB (0.36) POLBCFTRKMT2AMEN1HPGD
SCHEMBL24986217 0.92 POLB (0.35) POLBCFTRKMT2AMEN1HPGD
SCHEMBL24986216 0.92 POLB (0.35) POLBCFTRKMT2AMEN1HPGD
SCHEMBL24984639 0.92 POLB (0.35) POLBCFTRKMT2AMEN1HPGD
SCHEMBL24984633 0.92 POLB (0.35) POLBCFTRKMT2AMEN1HPGD
SCHEMBL18032900 0.92 POLB (0.37) POLBCFTRKMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230125803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ENANTA PHARM INC (US) 2023-04-27 US disclosed
US-11572367-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2023-02-07 US disclosed
US-20220119398-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS ENANTA PHARMACEUTICALS, INC. 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220119398-A1 HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS VIP, ACE, FURIN POLB 3294/4885CFTR 307/4885KMT2A 2438/4885
US-11572367-B2 Antiviral heterocyclic compounds ACE, HPRT1, ACE2 POLB 2743/4885CFTR 283/4885KMT2A 2570/4885
US-20230125803-A1 ANTIVIRAL HETEROCYCLIC COMPOUNDS ACE, HPRT1, ACE2 POLB 2743/4885CFTR 283/4885KMT2A 2570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.